From article on website..

 

"Parties with whom Sirona has had talks typically do not already have an SGLT-2 inhibitor in their pipeline, he noted...."

"Established diabetes players noticeably absent from the SGLT-2 space include Novo Nordisk (NOVOB:CPH), Sanofi (EPA:SAN), Merck (NYSE:MRK), and Takeda Pharmaceutical (TYO:4502)."